Get the right experience for you. Please select your location and investor type.
Why investors should care about Access to Medicines
Access to medicines latest research on Access to Generics is an important tool to help build a picture of areas where generics companies can continue improving and where investors can focus their engagement to drive better health and business outcomes, raising the bar for what affordable and accessible medicine means worldwide.
It is estimated that a woman dies from cervical cancer every 6 minutes in India.1 Despite cervical cancer being 90% preventable with effective vaccination, screening and treatment programs, more women die from cervical cancer in India than in any other country. This startling statistic highlights only one aspect of the very real problem of access to medicines.
The Healthcare gap
The generations living today have seen remarkable advances in global health over their lifetime. The ability to diagnose and treat a range of infectious and non-infectious diseases has vastly increased. Recent strides in producing vaccines using mRNA driven by the search for a COVID-19 vaccine have opened up the possibility of vaccinating against many other illnesses previously thought too difficult. The greater ease and lower cost of DNA testing are creating new areas of personalised medicine. And the development of biopharmaceuticals has led to new treatments for cancer, multiple sclerosis and other hard-to-treat, chronic conditions.
Despite these advances and their resulting benefit to human development, many essential medicines and healthcare products are unavailable and unaffordable for most of the world. The 80% of people in low and middle-income countries cannot even access basic vaccines and treatments, creating an unacceptable gap between the health outcomes of those in rich countries, and the billions of people in the rest of the world. This has devastating consequences, not just for the people in those countries but also for global heath security, as we recently saw in the COVID-19 pandemic.
Improving outcomes
The Access to Medicines Foundation2 is an independent, non-profit organisation with a mission to stimulate and guide essential healthcare companies to bring their products to the billions of people who cannot afford basic healthcare. Their flagship Access to Medicines Index seeks to identify best practice in each of the areas it measures. Once identified, these are shared to accelerate their uptake by other pharmaceutical companies, to help raise the level of standard practice and to achieve greater access to medicine. This has helped to drive improvements in affordable access, manufacturing practises and increasing research allocation towards significant unmet healthcare needs. But there is a lot more that can be done in the areas of generic medicines (drugs no longer protected by chemical patents), access to diagnostics and vaccines, amongst others.
At Stewart Investors, we’ve been using the Access to Medicines Index since it was first published to analyse the companies we seek to invest in and to guide our engagements with them. This year, in recognition of the importance of their work, we entered into a strategic research partnership with them. In the short term, this will support the Foundation in their vital work to promote access to high-quality generic medicines. More broadly, it will also support the positive change they create across the healthcare and investment industries.
Access to medicines is a sustainability issue and an important investment issue for long-term investors.
A franchise built on targeting a limited consumer base with expensive drugs is only sustainable for so long before it is eventually called into question by regulators, health care providers or the end consumers themselves. In contrast, providing available and affordable medicines to the 2 billion people living in low and middle-income countries creates a very large and growing consumer base. Rather than limiting a business to ageing populations that can afford the current high prices for medicines, finding businesses that can serve the customers of the future is a good starting point for investors.
Closing the gap: Roche
One example of a large global pharmaceutical company addressing the inequality gap is Roche*. Headquartered in Switzerland, Roche invests heavily into finding new and innovative medicines, treatments and diagnostics and sits in the top 10 of the Access to Medicines Index of 2022. It does not top the rankings due to its focus on biologic drugs to treat non-infectious diseases like cancer rather than a broader portfolio of medicines to tackle common infectious diseases. But even so, they have been tackling affordable access through a number of initiatives, including joining patent pools, applying international differential pricing and building healthcare capacity.
Building healthcare capacity is an important part of ensuring that medicines can reach those who need them. Roche launched a human papillomavirus self-sampling solution to expand cervical screening options for patients living in areas with limited healthcare resources. At the same time, they partnered with Pepal.org to create a Leadership Development Programme to combat cervical cancer in Tanzania, Uganda and India. This has led to greater awareness of cervical cancer, training of community health workers and increased screening and vaccinations in the target countries, as well as the development of leadership skills in the Roche workers who took part.
Why investors should care
Seeking out high-quality companies, stewarded by exceptional people, with strong financials that enable them to contribute to, and benefit from, sustainable development, is the cornerstone of our investment philosophy. When it comes to healthcare companies, how they address equitable pricing and access to medicines in emerging markets are useful indicators of the quality of management and resilience of franchise. The work done by the Access to Medicine Foundation is important for our investment process, and we are excited to see the publication of their latest research on Access to Generics. As investors, we see this as an important tool to help build a picture of areas where generics companies can continue improving and where investors can focus their engagements to drive better health and business outcomes, raising the bar for what affordable and accessible medicine means worldwide.
Subscribe to our updates
To get regular updates and content from Stewart Investors, please register here.
Important Information
This material is for general information purposes only. It does not constitute investment or financial advice and does not take into account any specific investment objectives, financial situation or needs. This is not an offer to provide asset management services, is not a recommendation or an offer or solicitation to buy, hold or sell any security or to execute any agreement for portfolio management or investment advisory services and this material has not been prepared in connection with any such offer. Before making any investment decision you should consider, with the assistance of a financial advisor, your individual investment needs, objectives and financial situation.
We have taken reasonable care to ensure that this material is accurate, current, and complete and fit for its intended purpose and audience as at the date of publication. To the extent this material contains any measurements or data related to environmental, social and governance (ESG) factors, these measurements or data are estimates based on information sourced by the relevant investment team from third parties including portfolio companies and such information may ultimately prove to be inaccurate. No assurance is given or liability accepted regarding the accuracy, validity or completeness of this material and we do not undertake to update it in future if circumstances change.
To the extent this material contains any expression of opinion or forward-looking statements, such opinions and statements are based on assumptions, matters and sources believed to be true and reliable at the time of publication only. This material reflects the views of the individual writers only. Those views may change, may not prove to be valid and may not reflect the views of everyone at First Sentier Investors.
To the extent this material contains any ESG related commitments or targets, such commitments or targets are current as at the date of publication and have been formulated by the relevant investment team in accordance with either internally developed proprietary frameworks or are otherwise based on the Institutional Investors Group on Climate Change (IIGCC) Paris Aligned Investment Initiative framework. The commitments and targets are based on information and representations made to the relevant investment teams by portfolio companies (which may ultimately prove not be accurate), together with assumptions made by the relevant investment team in relation to future matters such as government policy implementation in ESG and other climate-related areas, enhanced future technology and the actions of portfolio companies (all of which are subject to change over time). As such, achievement of these commitments and targets depend on the ongoing accuracy of such information and representations as well as the realisation of such future matters. Any commitments and targets set out in this material are continuously reviewed by the relevant investment teams and subject to change without notice.
About First Sentier Investors
References to ‘we’, ‘us’ or ‘our’ are references to First Sentier Investors, a global asset management business which is ultimately owned by Mitsubishi UFJ Financial Group. Certain of our investment teams operate under the trading names FSSA Investment Managers, Stewart Investors, RQI Investors and Igneo Infrastructure Partners, all of which are part of the First Sentier Investors group.
We communicate and conduct business through different legal entities in different locations. This material is communicated in:
- Australia and New Zealand by First Sentier Investors (Australia) IM Ltd, authorised and regulated in Australia by the Australian Securities and Investments Commission (AFSL 289017; ABN 89 114 194311)
- European Economic Area by First Sentier Investors (Ireland) Limited, authorised and regulated in Ireland by the Central Bank of Ireland (CBI reg no. C182306; reg office 70 Sir John Rogerson’s Quay, Dublin 2, Ireland; reg company no. 629188)
- Hong Kong by First Sentier Investors (Hong Kong) Limited and has not been reviewed by the Securities & Futures Commission in Hong Kong. First Sentier Investors, FSSA Investment Managers, Stewart Investors, RQI Investors and Igneo Infrastructure Partners are the business names of First Sentier Investors (Hong Kong) Limited.
- Singapore by First Sentier Investors (Singapore) (reg company no. 196900420D) and this advertisement or material has not been reviewed by the Monetary Authority of Singapore. First Sentier Investors (registration number 53236800B), FSSA Investment Managers (registration number 53314080C), Stewart Investors (registration number 53310114W), RQI Investors (registration number 53472532E) and Igneo Infrastructure Partners (registration number 53447928J) are the business divisions of First Sentier Investors (Singapore).
- Japan by First Sentier Investors (Japan) Limited, authorised and regulated by the Financial Service Agency (Director of Kanto Local Finance Bureau (Registered Financial Institutions) No.2611)
- United Kingdom by First Sentier Investors (UK) Funds Limited, authorised and regulated by the Financial Conduct Authority (reg. no. 2294743; reg office Finsbury Circus House, 15 Finsbury Circus, London EC2M 7EB)
- United States by First Sentier Investors (US) LLC, authorised and regulated by the Securities Exchange Commission (RIA 801-93167)
- other jurisdictions, where this document may lawfully be issued, by First Sentier Investors International IM Limited, authorised and regulated in the UK by the Financial Conduct Authority (FCA ref no. 122512; Registered office: 23 St. Andrew Square, Edinburgh, EH2 1BB; Company no. SC079063).
To the extent permitted by law, MUFG and its subsidiaries are not liable for any loss or damage as a result of reliance on any statement or information contained in this document. Neither MUFG nor any of its subsidiaries guarantee the performance of any investment products referred to in this document or the repayment of capital. Any investments referred to are not deposits or other liabilities of MUFG or its subsidiaries, and are subject to investment risk, including loss of income and capital invested.
© First Sentier Investors Group
